Antiverse sichert 9,3 Millionen US-Dollar in Serie-A-Finanzierung für KI-Antikörperplattform

UK-based Antiverse has secured $9.3 million in Series A funding, bolstering its AI-powered platform for discovering therapeutic antibodies. This investment, led by Soulmates Ventures, highlights growing confidence in European biotech's ability to leverage advanced technology for complex medical challenges. The funding aims to scale Antiverse's capabilities, positioning it to address previously untreatable diseases. Antiverse's innovative approach utilizes machine learning to design antibodies against "undruggable" molecular targets, a significant hurdle in modern medicine. The company combines computational design with in-house laboratory validation, employing proprietary cell systems to replicate human physiological conditions for rigorous testing. This integrated methodology aims to dramatically improve the efficiency of antibody discovery, a field historically plagued by high attrition rates. This advancement directly impacts the pharmaceutical industry and patient communities facing difficult-to-treat conditions like cancer, neurological disorders, and rare genetic diseases. The company's collaboration with the Cystic Fibrosis Foundation exemplifies its commitment to accelerating therapeutic development for historically challenging targets. The new capital will facilitate the expansion of Antiverse's partner programs and advance its internal drug pipeline towards crucial in vivo efficacy studies.